CEO SUMMARY: To create more transparency in the process clinical labs use to submit claims for genetic tests, molecular diagnostic tests, and for laboratory-developed tests (LDT), the nation’s largest Medicare Administrative Contractor (MAC) has proposed two new local coverage determinations (LCD). CMS has changed Palmetto GBA’s statement of work to include implementing a lab test […]
Palmetto Execs Explain Molecular Test Policies
Goal is to create a process to assess science and clinical value for molecular tests and LDTs
- By Joseph Burns
- > From the Volume XVIII No. 16 - November 28, 2011 Issue
- Tags: clinical lab, clinical laboratories, Clinical Laboratory, clinical labs, dark report, diagnostic testing, Diagnostic tests, ehi, genetic test, genetic tests, lab administrator, lab industry, lab test, lab tests, laboratories, laboratory test, laboratory tests, ldt, local coverage determination, local coverage determinations, Medicare, Medicare Administrative Contractor, MolDx, molecular assay, molecular assays, molecular diagnostic, molecular diagnostic services, molecular diagnostic test, molecular diagnostic testing, molecular diagnostic tests, molecular tests, pathologists, Pathology group, pathology groups, private payer, routine lab test, routine lab tests, the dark report, the laboratory
